Valuation: H. Lundbeck A/S

Capitalization 39.95B 6.26B 5.35B 4.9B 4.63B 8.58B 599B 8.62B 58.34B 22.71B 284B 23.49B 23B 988B P/E ratio 2026 *
9.04x
P/E ratio 2027 * 9.13x
Enterprise value 43.96B 6.89B 5.88B 5.39B 5.1B 9.44B 659B 9.49B 64.19B 24.99B 313B 25.85B 25.31B 1,088B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.55x
Free-Float
30.76%
Yield 2026 *
3.64%
Yield 2027 * 3.6%
1 day-0.43%
1 week-2.77%
Current month-3.50%
1 month+2.94%
3 months+5.99%
6 months-9.25%
Current year-4.12%
1 week 41.38
Extreme 41.38
45.76
1 month 40.78
Extreme 40.78
45.76
Current year 35.3
Extreme 35.3
47.04
1 year 32.74
Extreme 32.74
47.78
3 years 27.2
Extreme 27.2
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 66 24/03/2015
Director/Board Member 60 19/03/2018
Change 5d. change 1-year change 3-years change Capi.($)
-0.43%-2.77%+35.49%+12.88% 6.26B
+0.34%-0.87%+7.18%+89.04% 88.61B
+2.08%-2.68%+25.69%+119.83% 43.64B
0.00%-1.04%-3.38%+308.57% 23.89B
-0.86%-0.09%-14.71%-17.53% 8.59B
-0.58%-0.64%-7.14%-22.61% 8.41B
-0.98%-3.31%-1.90%-32.17% 7.29B
-1.27%-0.30%-2.44%+7.62% 5.22B
0.00%-0.78%-3.24%-12.38% 3.72B
-1.57%-3.00%+20.10%+26.73% 3.6B
Average -0.33%-1.99%+5.57%+48.00% 19.92B
Weighted average by Cap. +0.43%-4.73%+8.77%+100.82%

Financials

2026 *2027 *
Net sales 25.52B 4B 3.42B 3.13B 2.96B 5.48B 383B 5.51B 37.27B 14.51B 182B 15.01B 14.69B 631B 25.62B 4.02B 3.43B 3.14B 2.97B 5.5B 384B 5.53B 37.42B 14.57B 182B 15.07B 14.75B 634B
Net income 4.68B 734M 627M 574M 543M 1.01B 70.25B 1.01B 6.84B 2.66B 33.34B 2.75B 2.7B 116B 4.74B 743M 635M 582M 550M 1.02B 71.13B 1.02B 6.92B 2.7B 33.76B 2.79B 2.73B 117B
Net Debt 4.01B 629M 537M 492M 465M 861M 60.19B 866M 5.86B 2.28B 28.56B 2.36B 2.31B 99.28B -327M -51.28M -43.79M -40.12M -37.93M -70.24M -4.91B -70.6M -478M -186M -2.33B -192M -188M -8.09B
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,039
Date Price Change Volume
13/05/26 41.38 kr -0.43% 653,655
12/05/26 41.56 kr -1.75% 2,211,487
11/05/26 42.30 kr -1.76% 553,064
08/05/26 43.06 kr +0.19% 438,447
07/05/26 42.98 kr +0.99% 326,481
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
41.38DKK
Average target price
47.12DKK
Spread / Average Target
+13.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock